CSL in the news
Biotechnology medicines and vaccines
Tamtam found 13 recent articles about CSL.
- CSL shares: Buy, hold, or sell?
CSL shares are recovering, with the company aiming to improve plasma collection efficiency and expecting steady earnings growth through 2030.
- Will CSL's Alentis Deal Reset Its Kidney Strategy (ASX:CSL)?
CSL has signed an exclusive global partnership with Alentis Therapeutics to develop and commercialize lixudebart, an experimental antibody for rare kidney and liver diseases, enhancing CSL's nephrology strategy.
- CSL Limited (ASX:CSL): FY2026 Earnings Reflect Impairments and Biopharmaceutical Operations
CSL reported US$15.8 billion in FY2026 operating revenue, but a statutory net loss due to significant impairment and restructuring charges, alongside strong underlying profit and cash flow.
- CSL vaccines unit slammed over UK compliance failures
CSL's vaccines unit was sanctioned in the UK for failing to disclose significant payments to a French healthcare organization.
- CSL vs CBA: Which ASX share is best for SMSFs?
This article compares CSL (biotechnology) and Commonwealth Bank of Australia (banking) as investment options for Self-Managed Super Funds, ultimately recommending CBA for its fully franked dividends and stability despite CSL's growth potential.
- CSL to drop Terumo for Haemonetics in US plasma collection supply deal
CSL Plasma is switching its U.S. plasma collection supply from Terumo BCT to Haemonetics, deploying Haemonetics' NexSys PCS platform across all its U.S. centers by 2027.
- CSL Seqirus blasted for ‘multiple and prolonged deficiencies’
CSL Seqirus received a harsh rebuke from a UK watchdog for systemic failures in disclosing over £700,000 in payments to a healthcare organization.
- Haemonetics shares jump as CSL sets 2027 rollout of plasma devices
CSL will transition its US plasma collection centers to Haemonetics' devices by the end of 2027.
- CSL (ASX:CSL) Backs Lixudebart As Investors Ask If The Undervalued View Still Holds
CSL has invested heavily in a new drug partnership, causing its stock to rally, yet it remains undervalued according to market narratives despite potential risks.
- CSL announces investment for share of Alentis rare kidney and liver candidate
CSL invested US$355 million upfront in Alentis Therapeutics to co-develop lixudebart, an experimental antibody targeting rare kidney and liver diseases, with potential for significant commercial milestones and future earnings.
- CSL Strikes New Deal as Shares Enjoy Rare Period Of Consolidation
CSL acquired co-development rights for Alentis Therapeutics' lixudebart, an experimental monoclonal antibody, for an upfront payment of US$355 million and potential milestones, expanding its nephrology franchise.
- Australian Shares Flat; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug
CSL partnered with Alentis Therapeutics to develop a drug for rare kidney and liver diseases, while Australian shares remained flat due to economic data.
- CSL signs deal with Trump administration to slash prices for its medicines
CSL signed agreements with the Trump administration to reduce medicine prices in the US to avoid tariffs and ensure price comparability with other countries.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like CSL?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies